Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.

Cancer research communications·2026
Same author

Challenges for first-line therapy in elderly patients with metastatic non-small cell lung cancer.

Translational lung cancer research·2026
Same author

ILD with datopotamab deruxtecan combinations: a warning signal we should not ignore.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

<i>Aspergillus</i> serology for chronic pulmonary aspergillosis diagnosis: optimization of an enzyme-linked immunosorbent assay kit and assessment of a Western blot kit performance.

Journal of clinical microbiology·2026
Same author

Preventing infusion-related reactions: the lessons learn with the use of amivantamab.

Journal of thoracic disease·2026
Same author

Integrative and interactive genomic analyses guiding personalized combined therapy improve clinical benefit in metastatic patients: A monocentric real-life experience.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Related Experiment Video

Updated: Sep 11, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Alectinib Efficacy Post-Brigatinib Against Advanced ALK+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study).

Renaud Descourt1, Florian Guisier2, Maurice Pérol3

  • 1Hopital La Cavale Blanche, CHU Brest, Brest, France.

Lung Cancer (Auckland, N.Z.)
|August 18, 2025
PubMed
Summary

Alectinib showed limited efficacy after brigatinib treatment in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer patients. However, it may be a viable option, particularly if brigatinib was stopped due to toxicity.

Keywords:
ALK+ non-small cell lung canceralectinibbrigatinibmanagement

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

261
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Related Experiment Videos

Last Updated: Sep 11, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

261
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Brigatinib and alectinib are effective anaplastic lymphoma kinase inhibitors (ALKi) for advanced ALK-positive non-small-cell lung cancer (NSCLC).
  • Limited real-world data exists on alectinib's efficacy following brigatinib treatment failure.

Purpose of the Study:

  • To assess the real-world efficacy of alectinib in patients with advanced ALK-positive NSCLC who previously received brigatinib.

Main Methods:

  • Retrospective analysis of patients treated with alectinib after brigatinib within an early-access program (EAP).
  • Primary endpoint: alectinib median progression-free survival (mPFS) assessed by local investigators.

Main Results:

  • Of 30 patients who received alectinib post-brigatinib, mPFS was 4.8 months when given immediately after brigatinib.
  • Median overall survival (mOS) was 27 months for patients receiving alectinib immediately post-brigatinib.
  • Alectinib showed limited activity, especially when other treatments were administered between brigatinib and alectinib.

Conclusions:

  • Alectinib demonstrates limited overall activity after brigatinib failure in advanced ALK-positive NSCLC.
  • Alectinib remains a potential treatment option, particularly when brigatinib discontinuation was due to toxicity.